Robert Hawkins
Chief Tech/Sci/R&D Officer at INSTIL BIO, INC.
Net worth: 31 977 $ as of 30/03/2024
Profile
Robert Edward Hawkins is the founder of Instil Bio (UK) Ltd.
He currently holds the position of Head-Research & Development at Instil Bio, Inc. and Independent Non-Executive Director at BiVictriX Therapeutics Plc.
In the past, he served as a Director at Instil Bio, Inc. and as an Independent Non-Executive Director at Motif Bio Plc.
He was also an Honorary Professor at The University of Manchester.
Hawkins received his undergraduate and doctorate degrees from the University of Cambridge and his doctorate degree from University College London.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 30/12/2022 | 225,000 ( 0.27% ) | 31 977 $ | 30/03/2024 |
Robert Hawkins active positions
| Companies | Position | Start |
|---|---|---|
| BIVICTRIX THERAPEUTICS PLC | Director/Board Member | 21/09/2021 |
| INSTIL BIO, INC. | Chief Tech/Sci/R&D Officer | 10/11/2022 |
Former positions of Robert Hawkins
| Companies | Position | End |
|---|---|---|
| INSTIL BIO, INC. | Director/Board Member | 30/06/2020 |
| Instil Bio (UK) Ltd. | Chief Executive Officer | 31/12/2019 |
| The University of Manchester | Corporate Officer/Principal | - |
| MOTIF BIO PLC | Director/Board Member | - |
Training of Robert Hawkins
| University of Cambridge | Doctorate Degree |
| University College London | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| BIVICTRIX THERAPEUTICS PLC | Health Technology |
| INSTIL BIO, INC. | Health Technology |
| Private companies | 2 |
|---|---|
| Instil Bio (UK) Ltd. | |
Motif Bio Plc
 Motif Bio Plc Pharmaceuticals: MajorHealth Technology Motif Bio Plc is a clinical stage biopharmaceutical company, which engages in the development and commercialization of pharmaceutical formulations. The company focuses on developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. It offers Iclaprim, a novel diaminopyrimidine antibiotic that inhibits an essential bacterial enzyme called dihydrofolate reductase. The company was founded by Jonathan E. Gold on November 20, 2014 and is headquartered in Princeton, NJ. | Health Technology |
- Stock Market
- Insiders
- Robert Hawkins
